| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/27/2023 | 27.3% | UBS | → $38 | Initiates Coverage On | → Buy |
| 08/07/2023 | 34% | Barclays | $35 → $40 | Maintains | Overweight |
| 07/10/2023 | 17.25% | Barclays | $34 → $35 | Maintains | Overweight |
| 06/12/2023 | 20.6% | Citigroup | $33 → $36 | Maintains | Buy |
| 05/19/2023 | 17.25% | Argus Research | $32 → $35 | Maintains | Buy |
| 05/10/2023 | 13.9% | Barclays | $31 → $34 | Maintains | Overweight |
| 05/05/2023 | 10.55% | Citigroup | $30 → $33 | Maintains | Buy |
| 03/28/2023 | -6.2% | Goldman Sachs | $25 → $28 | Maintains | Neutral |
| 03/27/2023 | -6.2% | Goldman Sachs | $25 → $28 | Maintains | Neutral |
| 03/17/2023 | -16.25% | Credit Suisse | $21 → $25 | Maintains | Neutral |
| 02/21/2023 | -16.25% | Goldman Sachs | $22 → $25 | Maintains | Neutral |
| 02/17/2023 | 0.5% | Citigroup | $22 → $30 | Maintains | Buy |
| 12/13/2022 | -29.65% | Credit Suisse | → $21 | Initiates Coverage On | → Neutral |
| 12/12/2022 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 12/01/2022 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
| 11/04/2022 | -26.3% | Goldman Sachs | $25 → $22 | Maintains | Neutral |
| 11/04/2022 | -19.6% | Credit Suisse | $28 → $24 | Maintains | Outperform |
| 10/11/2022 | -16.25% | Goldman Sachs | $28 → $25 | Maintains | Neutral |
| 10/03/2022 | 0.5% | Barclays | $33 → $30 | Maintains | Overweight |
| 07/08/2022 | 10.55% | Barclays | $39 → $33 | Maintains | Overweight |
| 06/23/2022 | -12.9% | Goldman Sachs | $31 → $26 | Maintains | Neutral |
| 05/06/2022 | 7.2% | Credit Suisse | $30 → $32 | Maintains | Outperform |
| 04/07/2022 | -2.85% | Goldman Sachs | $33 → $29 | Maintains | Neutral |
| 04/04/2022 | 34% | Barclays | $42 → $40 | Maintains | Overweight |
| 02/18/2022 | 40.7% | Barclays | $50 → $42 | Maintains | Overweight |
| 02/18/2022 | 3.85% | Credit Suisse | $40 → $31 | Maintains | Outperform |
| 02/18/2022 | -2.85% | Baird | $45 → $29 | Downgrades | Outperform → Neutral |
| 08/09/2021 | 54.1% | Credit Suisse | $44 → $46 | Maintains | Outperform |
| 07/08/2021 | 50.75% | Bernstein | → $45 | Initiates Coverage On | → Buy |
| 06/03/2021 | 34% | Goldman Sachs | → $40 | Initiates Coverage On | → Neutral |
| 05/27/2021 | 23.95% | JP Morgan | → $37 | Initiates Coverage On | → Neutral |
| 05/20/2021 | 34% | Argus Research | → $40 | Upgrades | Hold → Buy |
What is the target price for Vontier (VNT)?
The latest price target for Vontier (NYSE: VNT) was reported by UBS on September 27, 2023. The analyst firm set a price target for $38.00 expecting VNT to rise to within 12 months (a possible 27.30% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vontier (VNT)?
The latest analyst rating for Vontier (NYSE: VNT) was provided by UBS, and Vontier initiated their buy rating.
When is the next analyst rating going to be posted or updated for Vontier (VNT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vontier, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vontier was filed on September 27, 2023 so you should expect the next rating to be made available sometime around September 27, 2024.
Is the Analyst Rating Vontier (VNT) correct?
While ratings are subjective and will change, the latest Vontier (VNT) rating was a initiated with a price target of $0.00 to $38.00. The current price Vontier (VNT) is trading at is $29.85, which is within the analyst's predicted range.